Qinghai Spring Medicinal Resources Technology Past Earnings Performance
Past criteria checks 0/6
Qinghai Spring Medicinal Resources Technology's earnings have been declining at an average annual rate of -48.2%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 16% per year.
Key information
-48.2%
Earnings growth rate
-48.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -16.0% |
| Return on equity | -19.2% |
| Net Margin | -146.9% |
| Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Qinghai Spring Medicinal Resources Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 192 | -282 | 229 | 12 |
| 30 Jun 23 | 162 | -289 | 216 | 12 |
| 31 Mar 23 | 141 | -293 | 212 | 12 |
| 31 Dec 22 | 160 | -288 | 214 | 11 |
| 30 Sep 22 | 175 | -264 | 242 | 10 |
| 30 Jun 22 | 186 | -248 | 224 | 8 |
| 31 Mar 22 | 183 | -263 | 224 | 9 |
| 31 Dec 21 | 128 | -249 | 177 | 10 |
| 30 Sep 21 | 143 | -276 | 124 | 10 |
| 30 Jun 21 | 138 | -305 | 138 | 14 |
| 31 Mar 21 | 132 | -311 | 127 | 13 |
| 31 Dec 20 | 124 | -320 | 131 | 12 |
| 30 Sep 20 | 128 | -69 | 108 | 11 |
| 30 Jun 20 | 135 | -61 | 117 | 5 |
| 31 Mar 20 | 174 | -20 | 114 | 5 |
| 31 Dec 19 | 234 | 6 | 116 | 4 |
| 30 Sep 19 | 248 | -25 | 153 | 6 |
| 30 Jun 19 | 277 | -11 | 158 | 4 |
| 31 Mar 19 | 305 | 33 | 160 | 3 |
| 31 Dec 18 | 333 | 68 | 147 | 3 |
| 30 Sep 18 | 358 | 186 | 103 | 1 |
| 30 Jun 18 | 441 | 309 | 69 | 3 |
| 31 Mar 18 | 452 | 316 | 54 | 2 |
| 31 Dec 17 | 471 | 311 | 59 | 2 |
| 30 Sep 17 | 646 | 346 | 56 | 1 |
| 30 Jun 17 | 671 | 275 | 72 | 0 |
| 31 Mar 17 | 705 | 260 | 93 | 0 |
| 31 Dec 16 | 708 | 245 | 116 | 0 |
| 30 Sep 16 | 876 | 255 | 153 | 0 |
| 30 Jun 16 | 1,115 | 352 | 167 | 0 |
| 31 Mar 16 | 1,187 | 365 | 182 | 0 |
| 31 Dec 15 | 1,402 | 358 | 282 | 0 |
| 30 Sep 15 | 1,466 | 242 | 415 | 0 |
| 30 Jun 15 | 1,527 | 225 | 440 | 0 |
| 31 Mar 15 | 1,844 | 285 | 508 | 0 |
| 31 Dec 14 | 2,063 | 365 | 510 | 0 |
| 31 Dec 13 | 2,141 | 337 | 542 | 0 |
Quality Earnings: 600381 is currently unprofitable.
Growing Profit Margin: 600381 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600381 is unprofitable, and losses have increased over the past 5 years at a rate of 48.2% per year.
Accelerating Growth: Unable to compare 600381's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 600381 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.5%).
Return on Equity
High ROE: 600381 has a negative Return on Equity (-19.17%), as it is currently unprofitable.